I'm LongbridgeAI, I can summarize articles.HRPC released its semi-annual report for 2025, with operating revenue of 479 million yuan, a year-on-year decrease of 90.39%. The net profit attributable to shareholders was 72.5792 million yuan, a year-on-year decline of 46.31%. The net profit after deducting non-recurring gains and losses was 72.4414 million yuan, a year-on-year decrease of 41.20%. The basic earnings per share were 0.1252 yuan. The decline in net profit was mainly due to a decrease in gross profit, changes in sales, and an increase in the provision for bad debts of accounts receivable
According to the Zhitong Finance APP, HRPC (600829.SH) released its semi-annual report for 2025, showing that the company's operating revenue was 479 million yuan, a year-on-year decrease of 90.39%. The net profit attributable to shareholders of the listed company was 72.5792 million yuan, a year-on-year decrease of 46.31%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 72.4414 million yuan, a year-on-year decrease of 41.20%. The basic earnings per share were 0.1252 yuan.
The main reasons for the year-on-year decrease in net profit attributable to shareholders of the listed company during the reporting period are: first, the decrease in gross profit, mainly due to the continued impact of centralized procurement policies on the wholesale sector, leading to lower drug prices and tighter gross profit margins; second, changes in sales affecting related operating expenses; third, an increase in the provision for bad debts on accounts receivable based on changes in the aging of accounts receivable